Improving Survival During Heart Transplantation: Diagnosis of antibody-mediated Rejection and Techniques for the Prevention of Graft Injury

• Billingham ME . Endomyocardial biopsy detection of acute rejection in cardiac allograft recipients. Heart Vessels Suppl., 1, 86–90 (1985).
   PubMedGoogle Scholar
• Subherwal S , KobashigawaJA, CogertG, PatelJ, EspejoM, OeserB. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant. Proc., 36(10), 3171–3172 (2004).
   PubMed Web of Science ®Google Scholar
• Herskowitz A , SouleLM, UedaKet al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients. J. Heart Transplant. , 6(3), 127–136 (1987).
   PubMedGoogle Scholar
• Hammond E , YowellR, NunodaSet al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J. Heart Lung Transplant. , 9(4), 447–449 (1998).
   Google Scholar
• Michaels PJ , EspejoML, KobashigawaJet al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J. Heart Lung Transplant. , 22(1), 58–69 (2003).
   PubMed Web of Science ®Google Scholar
• Salomon RN , HughesCC, SchoenFJ, PayneDD, PoberJS, LibbyP. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am. J. Pathol., 138(4), 791–798 (1991).
   PubMed Web of Science ®Google Scholar
• Labarrere CA , PittsD, NelsonDR, FaulkWP. Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant. Proc., 27(3), 1939–1940 (1995).
   PubMed Web of Science ®Google Scholar
• Colvin RB , SmithRN. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol., 5(10), 807–817 (2005).
   PubMed Web of Science ®Google Scholar
• Baldwin WM 3rd, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER. Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am. J. Transplant., 4(3), 311–318 (2004).
   PubMed Web of Science ®Google Scholar
• Morrell CN , MurataK, SwaimAMet al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ. Res., 102(7), 777–785 (2008).
   PubMed Web of Science ®Google Scholar
• Labarrere CA , NelsonDR, FaulkWP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA, 278(14), 1169–1175 (1997).
   PubMed Web of Science ®Google Scholar
• Hirohashi T , ChaseCMet al., Della Pelle P A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am. J. Transplant., 12(2), 313–321 (2011).
   PubMed Web of Science ®Google Scholar
• Stewart S , WintersGL, FishbeinMCet al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. , 24(11), 1710–1720 (2005).
   PubMed Web of Science ®Google Scholar
• Wu GW , KobashigawaJA, FishbeinMCet al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J. Heart Lung Transplant. , 28(5), 417–422 (2009).
   PubMed Web of Science ®Google Scholar
• Kfoury AG , HammondME, SnowGLet al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J. Heart Lung Transplant. , 28(8), 781–784 (2009).
   PubMed Web of Science ®Google Scholar
• Kfoury AG , HammondME. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J. Heart Lung Transplant., 29(4), 389–394 (2010).
   PubMed Web of Science ®Google Scholar
• Kobashigawa J , Crespo-LeiroMG, EnsmingerSMet al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. , 30(3), 252–269 (2011).
   PubMed Web of Science ®Google Scholar
• Berry GJ , AngeliniA, BurkeMMet al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005–2011). J. Heart Lung Transplant. , 30(6), 601–611 (2011).
   PubMed Web of Science ®Google Scholar
• John R , LietzK, SchusterMet al. Immunologic sensitization in recipients of left ventricular assist devices. J. Thorac. Cardiovasc. Surg. , 125(3), 578–591 (2003).
   PubMed Web of Science ®Google Scholar
• Hammond EH , YowellRL, NunodaSet al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J. Heart Transplant. , 8(6), 430–443 (1989).
   PubMedGoogle Scholar
• Kfoury AG , StehlikJ, RenlundDGet al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J. Heart Lung Transplant. , 25(11), 1277–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Reed EF , DemetrisAJ, HammondEet al. Acute antibody-mediated rejection of cardiac transplants. J. Heart Lung Transplant. , 25(2), 153–159 (2006).
   PubMed Web of Science ®Google Scholar
• Hooper DK , HawkinsJA, FullerTC, ProfaizerT, ShaddyRE. Panel-reactive antibodies late after allograft implantation in children. Ann. Thorac. Surg., 79(2), 641–644; Discussion 645 (2005).
   PubMed Web of Science ®Google Scholar
• John R , BoyleA, PaganiF, MillerL. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. J. Cardiovasc. Transl. Res., 2(2), 154–158 (2009).
   PubMed Web of Science ®Google Scholar
• Reed E , BeerAE, HutchersonH, KingDW, Suciu-FocaN. The alloantibody response of pregnant women and its suppression by soluble HLA antigens and anti-idiotypic antibodies. J. Reprod. Immunol., 20(2), 115–128 (1991).
   PubMed Web of Science ®Google Scholar
• Arnaoutakis GJ , GeorgeTJ, KilicAet al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. J. Thorac. Cardiovasc. Surg. , 142(5), 1236.e1–1245.e1, (2011).
   Web of Science ®Google Scholar
• Massad MG , CookDJ, SchmittSKet al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann. Thorac. Surg. , 64(4), 1120–1125 (1997).
   PubMed Web of Science ®Google Scholar
• John R , RajasingheH, ChenJMet al. Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients. Ann. Surg. , 232(3), 302–311 (2000).
   PubMed Web of Science ®Google Scholar
• Drakos SG , KfouryAG, KotterJRet al. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J. Heart Lung Transplant. , 28(8), 838–842 (2009).
   PubMed Web of Science ®Google Scholar
• George I , ColleyP, RussoMJet al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J. Thorac. Cardiovasc. Surg. , 135(6), 1372–1379 (2008).
   PubMed Web of Science ®Google Scholar
• Coppage M , BakerM, FialkowLet al. Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products. Hum. Immunol. , 70(6), 413–416 (2009).
   PubMed Web of Science ®Google Scholar
• Nwakanma LU , WilliamsJA, WeissES, RussellSD, BaumgartnerWA, ConteJV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann. Thorac. Surg., 84(5), 1556–1562; Discussion 1562–1563 (2007).
   PubMed Web of Science ®Google Scholar
• Tinckam KJ , ChandrakerA. Mechanisms and role of HLA and non-HLA alloantibodies. Clin. J. Am. Soc. Nephrol., 1(3), 404–414 (2006).
   PubMed Web of Science ®Google Scholar
• Schlaf G , Pollok-KoppB, ManzkeT, SchuratO, AltermannW. Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching. NDT Plus, 3(6), 527–538 (2010).
   PubMedGoogle Scholar
• Altermann WW , SeligerB, SelS, WendtD, SchlafG. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histol. Histopathol., 21(10), 1115–1124 (2006).
   PubMed Web of Science ®Google Scholar
• Smith JD , HamourIM, BannerNR, RoseML. C4d fixing, luminex binding antibodies – a new tool for prediction of graft failure after heart transplantation. Am. J. Transplant., 7(12), 2809–2815 (2007).
   PubMed Web of Science ®Google Scholar
• Won DI , JungHD, JungOJ, HuhS, SuhJS. Flow cytometry PRA using lymphocyte pools from random donors. Cytometry B. Clin. Cytom., 72(4), 256–264 (2007).
   PubMedGoogle Scholar
• El-Awar N , LeeJ, TerasakiPI. HLA antibody identification with single antigen beads compared to conventional methods. Hum. Immunol., 66(9), 989–997 (2005).
   PubMed Web of Science ®Google Scholar
• Stehlik J , IslamN, HurstDet al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J. Heart Lung Transplant. , 28(11), 1129–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Zangwill S , EllisT, StendahlG, ZahnA, BergerS, TweddellJ. Practical application of the virtual crossmatch. Pediatr. Transplant., 11(6), 650–654 (2007).
   PubMed Web of Science ®Google Scholar
• Kobashigawa J , MehraM, WestLet al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J. Heart Lung Transplant. , 28(3), 213–225 (2009).
   PubMedGoogle Scholar
• Pisani BA , MullenGM, MalinowskaKet al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J. Heart Lung Transplant. , 18(7), 701–706 (1999).
   PubMed Web of Science ®Google Scholar
• Jordan SC , ToyodaM, VoAA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation, 88(1), 1–6 (2009).
   PubMed Web of Science ®Google Scholar
• John R , LietzK, BurkeEet al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation , 100(Suppl. 19), II229–II235 (1999).
   PubMed Web of Science ®Google Scholar
• Vo AA , LukovskyM, ToyodaMet al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. , 359(3), 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA , PatelJK, KittlesonMMet al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin. Transplant. , 25(1), E61–E67 (2011).
   PubMed Web of Science ®Google Scholar
• Perry DK , BurnsJM, PollingerHSet al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. , 9(1), 201–209 (2009).
   PubMed Web of Science ®Google Scholar
• Idica A , KanekuH, EverlyMJet al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin. Transpl. 229–239 (2008).
   PubMedGoogle Scholar
• Trivedi HL , TerasakiPI, FerozAet al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation , 87(10), 1555–1561 (2009).
   PubMed Web of Science ®Google Scholar
• Patel J , EverlyM, ChangD, KittlesonM, ReedE, KobashigawaJ. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J. Heart Lung Transplant., 30(12), 1320–1326 (2011).
   PubMed Web of Science ®Google Scholar
• Takemoto SK , ZeeviA, FengSet al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant. , 4(7), 1033–1041 (2004).
   PubMed Web of Science ®Google Scholar
• Nair N , BallT, UberPA, MehraMR. Current and future challenges in therapy for antibody-mediated rejection. J. Heart Lung Transplant., 30(6), 612–617 (2011).
   PubMed Web of Science ®Google Scholar
• Olsen SL , WagonerLE, HammondEHet al. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J. Heart Lung Transplant. , 12(2), S135–S142 (1993).
   PubMed Web of Science ®Google Scholar
• Zand MS , VoT, HugginsJet al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation , 79(11), 1507–1515 (2005).
   PubMed Web of Science ®Google Scholar
• Bohmig GA , RegeleH, ExnerMet al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J. Am. Soc. Nephrol. , 12(11), 2482–2489 (2001).
   PubMed Web of Science ®Google Scholar
• Leech SH , Lopez-CeperoM, LeforWMet al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin. Transplant. , 20(4), 476–484 (2006).
   PubMed Web of Science ®Google Scholar
• Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann. Thorac. Surg., 74(4), 1240–1242 (2002).
   PubMed Web of Science ®Google Scholar
• Baran DA , LubitzS, AlviSet al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant. Proc. , 36(10), 3164–3166 (2004).
   PubMed Web of Science ®Google Scholar
• Everly MJ , EverlyJJ, SusskindBet al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation , 86(12), 1754–1761 (2008).
   PubMed Web of Science ®Google Scholar
• Walsh RC , EverlyJJ, BraileyPet al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation , 89(3), 277–284 (2010).
   PubMed Web of Science ®Google Scholar
• Stegall MD , DiwanT, RaghavaiahSet al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. , 11(11), 2405–2413 (2011).
   PubMed Web of Science ®Google Scholar
• Jin YP , FishbeinMC, SaidJWet al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum. Immunol. , 65(4), 291–302 (2004).
   PubMed Web of Science ®Google Scholar
• Jin YP , JindraPT, GongKW, LepinEJ, ReedEF. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation, 79(Suppl. 3), S19–S21 (2005).
   PubMed Web of Science ®Google Scholar
• Jindra PT , JinYP, RozengurtE, ReedEF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J. Immunol., 180(4), 2357–2366 (2008).
   PubMed Web of Science ®Google Scholar
• Keogh A , RichardsonM, RuygrokPet al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation , 110(17), 2694–2700 (2004).
   PubMed Web of Science ®Google Scholar
• Eisen HJ , TuzcuEM, DorentRet al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. , 349(9), 847–858 (2003).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA , MillerLW, RussellSDet al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant. , 6(6), 1377–1386 (2006).
   PubMed Web of Science ®Google Scholar
• Warren DS , ZacharyAA, SonnendayCJet al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am. J. Transplant. , 4(4), 561–568 (2004).
   PubMed Web of Science ®Google Scholar

Website

• United Network for Organ Sharing calculated panel reactive antibody calculator. http://optn.transplant.hrsa.gov/resources/professionalresources.asp?index=78 (Accessed 14June2012)
   Google Scholar